The Drugs for Neglected Diseases initiative (DNDi ) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as leishmaniasis, human African trypanosomiasis, Chagas disease, malaria, and, with the recent expansion of its portfolio, specific helminth-related infections and pediatric HIV. DNDi was founded in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, France's Pasteur Institute, Médecins Sans Frontières (MSF), and WHO/TDR which acts as a permanent observer to the initiative. DNDi's main headquarters are in Geneva, Switzerland.
Drugs for Neglected Diseases initiative (DNDi) North America was founded in 2007 as an affiliate of DNDi. It is a registered 501(c)(3) organization in the United States that works to strengthen and expand DNDi's scientific, advocacy, fundraising, communications, and partner development efforts in the region.
To improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases and by ensuring equitable access to new and field-relevant health tools. In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven R&D. They also build public responsibility and leadership in addressing the needs of these patients.